Alpha-MSH vs Teduglutide

Melanocortin peptide; activates MC1R (pigmentation/anti-inflammatory), MC3R (energy balance), MC4R (appetite); suppresses NF-κB and pro-inflammatory cytokines

α-Melanocyte-stimulating hormone (α-MSH) is an endogenous 13-amino-acid peptide derived from proteolytic processing of proopiomelanocortin (POMC) that acts through melanocortin receptors (MC1R–MC5R), with biological roles including skin pigmentation, anti-inflammatory signaling, thermoregulation, and energy homeostasis. Its anti-inflammatory actions are mediated principally through MC1R and MC3R activation, leading to inhibition of NF-κB-dependent cytokine production, reduction of pro-inflammatory mediators including IL-1β and TNF-α, and modulation of leukocyte activity in both peripheral and central nervous system compartments. Research published in the Annals of the New York Academy of Sciences has characterized the mechanisms of α-MSH's anti-inflammatory activity in vivo and in vitro, and subsequent work has described new insights into its immunomodulatory functions and therapeutic potential in inflammatory conditions. α-MSH is a research compound with no FDA approval for any indication; no human clinical trials have established safety or efficacy for exogenous α-MSH administration in anti-inflammatory, neuroprotective, or other therapeutic contexts. Alpha-MSH and the melanocortin peptide family α-MSH is the prototype endogenous ligand for the melanocortin receptor family — five receptors (MC1R–MC5R) with distinct tissue distribution and functions. The pharmacological development of synthetic melanocortin analogues has produced several clinically and commercially relevant compounds derived from or inspired by α-MSH: Melanotan I (afamelanotide, MC1R-selective, approved as Scenesse for erythropoietic protoporphyria), Melanotan II (non-selective, superpotent, never approved; extensively used in research), and PT-141/bremelanotide (cyclized Melanotan II analogue, FDA-approved as Vyleesi for female hypoactive sexual desire disorder via MC3R/MC4R). α-MSH itself serves as the structural reference point for this lineage — the pharmacophore binding sequence (His-Phe-Arg-Trp) shared by all active melanocortin analogues is derived from α-MSH residues 6–9. Appetite regulation and obesity research: α-MSH's role in energy homeostasis is mediated through MC4R activation in the hypothalamus, where it acts as an endogenous satiety signal opposing the appetitive effects of AgRP (agouti-related protein). Loss-of-function MC4R mutations are the most common monogenic cause of severe early-onset obesity, establishing the α-MSH/MC4R pathway as a validated target for pharmacological weight management. Setmelanotide (Imcivree), an MC4R agonist, is FDA-approved for obesity caused by MC4R pathway deficiency mutations (POMC deficiency, PCSK1 deficiency, leptin receptor deficiency) — a direct pharmacological descendant of the α-MSH mechanism.

GLP-2 receptor agonist; stimulates intestinal epithelial proliferation and reduces apoptosis; increases intestinal blood flow and inhibits gastric motility

Teduglutide (Gattex in the United States, Revestive in the European Union) is a GLP-2 analogue and FDA-approved prescription medication indicated for short bowel syndrome (SBS) with intestinal failure in adults and pediatric patients, designed to reduce dependence on parenteral nutrition and intravenous fluids by promoting intestinal mucosal growth and enhancing residual bowel absorptive capacity. By activating GLP-2 receptors on intestinal subepithelial myofibroblasts and enteric neurons, teduglutide stimulates paracrine release of insulin-like growth factor 1 (IGF-1) and keratinocyte growth factor (KGF), driving enterocyte crypt cell proliferation, increasing villus height, and expanding mucosal absorptive surface area to improve nutrient and fluid absorption from functionally compromised residual bowel. A systematic review and meta-analysis of Phase 3 registrational trial data published in the Journal of Parenteral and Enteral Nutrition documented significant reductions in parenteral nutrition volume requirements, and long-term follow-up data published in Clinical and Translational Gastroenterology confirmed durable reductions in parenteral support needs over extended treatment periods. Teduglutide is an FDA-approved prescription medication; it is indicated for adults and pediatric patients (≥1 year) with SBS dependent on parenteral support, and use outside this indication or without physician supervision is not supported by established safety and efficacy data.